Effects of a low-fat dietary regimen enriched with soy in children affected with heterozygous familial hypercholesterolemia

Abstract

Familial hypercholesterolemia (FH) is an inheritable, autosomal dominant disorder leading to pathologically increased levels of low-density-lipoprotein cholesterol (LDL-C). Dietary treatment remains an important tool in the management of affected children even after the decision for the initiation of pharmacotherapy is made. However, little evidence is available regarding the optimal dietary regimen for the treatment of children affected with FH. We present results from a randomized controlled trial in paediatric patients affected with heterozygous FH, assessing the effect of a soy-enriched fat modified diet (soy group) compared to fat modified diet (Control group) alone on LDL-C over a period of 13 weeks. Furthermore, we monitored isoflavone levels in plasma and urine as markers of adherence to the dietary treatments. LDL-C decrease was statistically significantly greater in the soy group compared to the control group at week 7 (Control group 176.3±27.8mg/dl, soy group 154.7±29.2mg/dl, p=0.038), and showed a trend towards significant at week 13 (Control group 179.9±41.8mg/dl, soy group 155.0±30.2mg/dl, p=0.089). Relative LDL-C decrease correlated significantly with the following plasma isoflavone concentrations measured in week 7: daidzein (p<0.004, r=0.576) and genistein (p<0.017, r=0.490). We provide evidence from a small randomized-controlled trial for the effectiveness and safety of a dietary treatment with soy in paediatric patients affected with heterozygous FH. The decrease in LDL-C was highly correlated with isoflavone levels, further highlighting a direct effect of soy ingestion. This study was registered under ClinicalTrials.gov Identifier No. NCT03563547.